To see the effect of Dapagliflozin in patients of Liver Cirrhosis with Ascites

Assessment of efficacy of Dapagliflozin in patients of Liver Cirrhosis with Ascites - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/076376

Enrollment

130

Registered

2024-11-08

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K703- Alcoholic cirrhosis of liver

Interventions

Intervention1: Dapagliflozin Group: Tablet Dapagliflozin 10mg orally once daily for 6 months in addition to standard medical treatment Control Intervention1: Furosemide and Spironolactone Group: Stand

Eligibility

Inclusion criteria

Inclusion criteria: All the patients of liver cirrhosis with new onset ascites and patients of ascites uncontrolled on diuretics therapy shall be enrolled.

Exclusion criteria

Exclusion criteria: Age less than 18 years, Cerebrovascular disorder, any neurological disorder including dementia/ Alzheimer’s etc., Pregnancy and Any extrahepatic malignancy.

Design outcomes

Primary

Measure	Time frame
Reduction in grade of AscitesTimepoint: 3 and 6 months.	—

Secondary

Measure	Time frame
Episodes of Acute kidney injury (AKI)/ spontaneous bacterial peritonitis/ hepatic encephalopathy/ jaundice and Change in CTP and MELD score.Timepoint: 3 and 6 months	—

Countries

India

Contacts

Public ContactDr Ravi Dhayal

Pt. B. D. Sharma Post Graduate Institute of Medical Sciences, Rohtak , Haryana

taranagupta@gmail.com9914048899

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026